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While extracellular serotonin is commonly used to assess the effects of long-term treatment with 
selective serotonin reuptake inhibitors, it is still not clear how this affects serotonergic markers 
like synthesis, storage and metabolism. It is conceivable that in order to maintain intracellular 
stores of serotonin, synthesis needs to adjust to the conditions of prolonged reuptake inhibition. 
In the present study, we investigated the effect of chronic SSRI treatment on serotonin, its 
metabolite HIAA and the precursor 5-hydroxy tryptophan in tissue of rat brain. It was found that 
chronic treatment resulted in a dramatic depletion of the serotonin content in the brain, which 
most likely is the result of insufficient serotonin synthesis caused by prolonged autoreceptor 
activation. 
In addition, we have demonstrated that a washout period rapidly reverses the effects of chronic 
treatment in terminal areas only, indicating a role for the 5-HT1B receptor. This might parallel the 
clinical phenomenon of rebound depression, which occurs when suddenly discontinuing 
treatment with antidepressants. These findings further support the clinical practice to slowly 
phase out SSRI treatment.  




The serotonergic system and consequently also its response to serotonergic drugs like 
antidepressants are known to be under tight control of a number of feedback mechanisms. 
Increased levels of serotonin (5-HT) caused by serotonergic reuptake inhibitors (SSRIs) activate 
several inhibitory autoreceptors controlling serotonergic synthesis (Moret and Briley, 
1997;Barton and Hutson, 1999;Hjorth et al., 1995), release (Invernizzi et al., 1997;Rollema et al., 
1996;Hjorth, 1993;Cremers et al., 2000) and turnover (Stenfors and Ross, 2002;Fuller, Perry et 
al., 1974). Starting chronic SSRI treatment, all processes immediately lessened, but steadily 
normalized or even increased during treatment (Kreiss and Lucki, 1995;Le Poul et al., 
1995;Esteban et al., 1999;Stenfors and Ross, 2002), suggesting a gradually reduced functionality 
of the serotonergic autoreceptors. It is generally believed that the increase of extracellular 
serotonin as a result of diminished autoreceptor control might underlie the therapeutic response 
to antidepressants (Blier, de Montigny et al., 1987;Briley and Moret, 1993). Whereas the effect 
of long term antidepressant treatment on serotonergic release, turnover and synthesis has been 
investigated extensively, it still remains unknown if intracellular serotonin stores are affected. 
Serotonergic cells partly rely on synthesis and partly on reuptake of extracellular serotonin to 
maintain their intracellular concentration. So theoretically, intracellular serotonin stores could get 
depleted if synthesis rate remains unadjusted while reuptake is continuously blocked by chronic 
treatment. 
 In the present study, we investigated the effect of chronic citalopram treatment on brain 
serotonin, synthesis and metabolism in tissue of several brain areas.  
The conversion of tryptophan into 5-HTP is considered to be the rate-limiting step in the 
synthesis of serotonin, as under normal conditions, 5-HTP is immediately converted into 5-HT 
by the non-specific enzyme aminoacid decarboxylase. The rate of serotonin synthesis was 
measured as the amount of 5-HTP accumulated when blocking this final step. The ratio of 5-
HIAA/5-HT was used as an index of serotonergic metabolism or turnover.  
As a marker of the serotonergic system, extracellullar serotonin measured by microdialysis is 
generally used to assess the effect of prolonged antidepressant treatment. However, this 
represents only a fraction of the total serotonin content in the brain as the amount stored 
intracellular is a 1000 fold higher. In the present study, tissue destruction was used to investigate 
effects on total levels of serotonin, HIAA and 5-HTP, which includes both intra- and 
extracellular levels, but merely represents the intracellular situation. Compared to extracellular 
measurements, this might give a better view of general changes in serotonergic homeostasis 
throughout the whole brain. 
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The effect of chronic treatment is commonly assessed by a challenge following a washout period 
in order to prevent pharmacological interference with the treatment. However, it has been shown 
that adaptive processes seen after chronic treatment can revert whithin the time span of the 
washout period (Neumaier, Root et al., 1996). This implies a rapid adaptation of the serotonergic 
system and also questions the effects observed after a washout. In the present study, citalopram 
was delivered by osmotic minipumps to ensure stable plasma levels and analyzed to evaluate 
kinetics. The effect of chronic treatment on a challenge with citalopram was studied both after a 
washout and in presence of the minipump. The latter could give a better insight in the effects of 
chronic treatment on the serotonergic homeostatis because it more closely resembles the clinical 
situation.   
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2. Materials and methods 
 
2.1 Animals 
Male Harlan rats (Zeist, Netherlands) weighing 285-320 g were housed eight per cage under 
standard conditions (22-24 oC, 12/12 light/dark cycle, food and water ad libitum). Following 
implantation of the minipump, rats were housed in pairs of two. All animal experiments were 
performed according to the governmental guidelines for care and use of laboratory animals and 
were approved by the Committee for Animal Research of the Medical Faculty of the Medical 
Faculty of the Groningen University. 
 
2.2 Treatment 
Osmotic minipumps (2ML2 Alzet, USA, 5 µl/h, 2 weeks) were either filled with saline or 50 
mg/ml citalopram hydrobromide dissolved in saline under aseptic conditions. During isoflurane 
anaesthesia (2,5%, 400 ml/min N2O, 600 ml/min O2), minipumps were implanted subcutaneously 
on the left side of the back of the rat.  
In the treatment group including a washout period, the osmotic minipumps were removed after 
14 days, the remaining subcutaneous cavity was flushed twice with 5 ml of sterile saline and 
animals were sacrified 48 hours after removal of their minipump. The other treatment groups 
include a 14 day saline treatment and a 14 day citalopram treatment, these animals were sacrified 
with their minipump still in place. 
At the day of the termination, animals were challenged with either citalopram 10 µmol/kg sc or 
saline. After 45 min. NSD 1015 was injected intraperitoneally at a dose of 100 mg/kg. Another 
45 min later, animals were anaesthetized with isoflurane anaesthesia (2,5 %, 400ml/min N2O, 
600 ml/min O2), blood was taken by cardiac puncture, brains were removed, rapidly frozen at dry 
ice and stored at –80 oC. 
 
2.3 Tissue dissection 
Brains were sliced on a cryostat and punches were taken from nine brain areas; anterior cingulate 
cortex (ACAD), nucleus accumbens (NAc), caudate putamen (CP), paraventricular nucleus of 
the hypothalamus (PVN), dorsal hippocampus (dHC), ventral hippocampus (vHC), central 
amygdala (Amy). Brain samples were homogenized with 100 µL of 0.1 M perchloric acid and 
centrifuged at 14000 rpm for 10 min at 4 oC. The supernatant was removed and assayed for 5-





The following drugs were used: Citalopram hydrobromide (kindly donated by Lundbeck 
(Denmark) courtesy Dr. Sanchez) and NSD 1015 (purchased from Sigma). 
 
2.5 Analytical procedures 
2.5.1. 5-HT, 5-HIAA and 5-HTP 
Analysis of 5-HT and 5-HIAA was performed by high-performance liquid chromatography 
(HPLC) with electrochemical detection. Briefly, 20 µl samples were injected into a HPLC 
(Shimadzu, LC-10AD liquid chromatograph) equipped with a reversed-phase column (phenomex 
hypersil 3 : 3 µm, 100 x 2.0 mm, C18, Bester, Amstelveen, the Netherlands) and an 
electrochemical detector (ESA, Chelmsford, MA, USA) at a potential setting of 600 mV vs. 
Ag/AgCl reference electrode. The mobile phase consisted of 4.1 g/l Na acetate , 150 mg/l octane 
sulphonic acid sodium salt, 10 % methanol, adjusted to pH 4.1 with acetic acid. 5-HTP was 
analyzed by adjusting the methanol content to 5%. The flow rate was 1.0 ml/min.  
2.5.2. Citalopram 
Citalopram was measured in plasma according to Oyehaug et al. (1982) with minor 
modifications. Dialysate samples were injected into an HPLC (1084B Liquid Chromatograph, 
Hewlett Packard) which was connected with a fluorescence detector (470 Scanning Fluorescence 
detector, Waters, England) operating at an absorption wavelength of 240 nm, an emission 
wavelenght of 296 nm, and a slitwidth of 12 nm. Separation was performed using a Supelcosil 
HPLC column (5 µm, C18, 250 x 46 mm, Supelco, the Netherlands), at ambient temperature. The 
mobile phase consisted of 46% v/v acetonitrile, 54% v/v potassium dihydrogen phosphate buffer 
(4.3 g/l) and 1 mM tetramethylammonium, at pH 3.0. The flow rate was set at 0.75 ml/min. The 
detection limit was 5 nM (signal to noise ratio = 2) 
 
2.6 Data processing and statistics 
Levels are depicted as percentage of the control group, the saline treated animals receiving a 
saline challenge. All data are depicted in table 1, results which are discussed are presented in 
grahps and have been statistically analyzed. Statistical analysis was performed using Sigmastat 
for windows (Jandel Software, SPPS Inc., Chicago, IL, USA). Treatment or challenge effects 
were evaluated using one way ANOVA. 




Effect treatment on intracellular serotonin stores 
Compared to saline treated animals, chronic treatment with a subsequent washout period of 48 
hours reduced intracellular serotonin throughout the brain, showing a statistical difference in the 
NAc (P = 0.0017), CP (P = 0.0063), dHC (P = 0.00816) and PVN (P = 0.0095). Following 
chronic treatment without washout, this effect was even stronger, now being statistically different 
in Acad (P = 0.0077), NAc (P = 0.0179), CP (P = 0.0402), dHC (P = 0.0044) and PVN (P = 
0.0007) (Fig. 1). 
 
Effect washout on treatment 
After a washout period of 48 hours, both turnover and synthesis were increased following 
chronic treatment. In absence of a washout period, these processes were decreased. Although a 
clear trend in all brainareas, this difference was significant in the Nac (P = 0.0016), vHC (P = 
0.0093), Amy (P = 0.0004) and PVN (P = 0.0117) for the turnover, synthesis statistically differed 
in Acad (P = 0.0257), CP (P = 0.0344), dHC (P = 0.0378), vHC (P = 0.0303), PVN (P = 0.0329) 
and DRN (P = 0.0417) (Figs. 2 and 3). 
 
Effect acute and chronic treatment with citalopram on plasma levels 
Obviously, following chronic saline treatment, a challenge with saline did not have any effect 
plasma levels of citalopram. An acute challenge of citalopram increased levels to 2.26 ± 0.28 µM 
(P<0.0001). A 48 hour washout period following a 14 day treatment with citalopram was 
sufficient to reduce the amount of citalopram below a functional level, as plasma levels were 
below detection limit. Challenging the animal subsequently with citalopram raised levels to 1.91 
± 0.15 µM (P<0.0001). Chronic treatment without a washout resulted in plasma levels of 1.44 ± 
0.05 µM, a challenge with citalopram increased plasma levels further to 3.38 ± 0.63 µM (P = 
0.0401). Plasma levels of citalopram following either acute administration or prolonged 
treatment without washout are comparable. As pharmacokinetics do not differ, group effects 





Fig. 1. Effect of chronic treatment on intracellular serotonin stores 
Black bars; saline treatment, saline challenge. Grey bars; citalopram treatment, 
48 hour washout, saline challenge. White bars; citalopram treatment, no 
washout, saline challenge. * P < 0.05 versus saline treatment. 
 
 
Fig. 2. Effect of washout on serotonin turnover 
Black bars; saline treatment, saline challenge. Grey bars; citalopram treatment, 
48 hour washout, saline challenge. White bars, citalopram treatment, no 
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Fig. 3. Effect of washout on serotonin synthesis 
Black bars; saline treatment, saline challenge. Grey bars; citalopram treatment, 
48 hour washout, saline challenge. White bars, citalopram treatment, no 
washout, saline challenge. * P < 0.05 washout versus no washout. 
 
 
Fig. 4. Effect acute and chronic treatment on plasma levels of citalopram 
Light grey bars; saline challenge. Dark grey bars; citalopram challenge. 
* P < 0.05 versus saline challenge, ** P < 0.05 versus other saline challenged 
groups. Saline 0 hrs = 14 day saline treatment; citalopram 48 hrs = 14 day 
citalopram treatment with 48 washout; citalopram 0 hrs = 14 day citalopram 

































































treatment saline saline saline citalopram citalopram
washout 0 hrs 0 hrs 0 hrs 48 hrs 0 hrs
challenge saline saline citalopram saline saline
5-HT fmol SEM % SEM % SEM % SEM % SEM
Acad 780,1 ± 191,4 100,0 ± 24,5 55,7 ± 6,5 51,2 ± 12,5 13,2 ± 1,7
Nac 663,8 ± 106,5 100,0 ± 16,0 90,1 ± 22,7 25,1 ± 2,5 41,7 ± 11,3
CP 370,6 ± 51,2 100,0 ± 13,8 51,9 ± 12,9 37,5 ± 9,5 52,7 ± 12,7
Amy 2059,8 ± 417,3 100,0 ± 20,3 67,5 ± 15,1 68,1 ± 7,3 59,8 ± 16,5
dHC 546,0 ± 43,1 100,0 ± 7,9 57,7 ± 4,2 63,4 ± 5,1 37,7 ± 13,8
PVN 1084,1 ± 121,0 100,0 ± 11,2 61,7 ± 3,9 55,1 ± 1,1 23,8 ± 9,1
vHC 1407,8 ± 445,2 100,0 ± 31,6 37,7 ± 9,7 61,5 ± 2,9 43,0 ± 12,6
DR 1676,5 ± 517,2 100,0 ± 30,8 95,9 ± 10,5 120,6 ± 6,9 70,9 ± 28,9
MRN 1328,5 ± 245,2 100,0 ± 18,5 92,2 ± 0,6 66,2 ± 7,9 41,5 ± 16,4
HIAA fmol SEM % SEM % SEM % SEM % SEM
Acad 483,7 ± 93,1 100,0 ± 19,3 61,4 ± 12,3 80,5 ± 17,9 18,3 ± 5,2
Nac 666,6 ± 145,7 100,0 ± 21,9 49,5 ± 8,0 48,6 ± 6,0 31,8 ± 4,1
CP 543,0 ± 98,0 100,0 ± 18,0 36,5 ± 3,8 44,7 ± 5,9 38,1 ± 1,8
Amy 557,1 ± 158,5 100,0 ± 28,5 79,8 ± 21,4 137,1 ± 32,0 42,0 ± 4,1
dHC 546,3 ± 91,9 100,0 ± 16,8 47,1 ± 5,0 87,1 ± 19,7 47,0 ± 7,2
PVN 310,6 ± 67,7 100,0 ± 21,8 71,6 ± 23,1 103,6 ± 21,4 25,8 ± 7,2
vHC 542,0 ± 141,3 100,0 ± 26,1 41,6 ± 6,2 130,6 ± 13,4 40,9 ± 5,0
DR 1019,0 ± 241,2 100,0 ± 23,7 50,7 ± 13,1 196,6 ± 13,8 58,9 ± 20,5
MRN 1072,0 ± 245,4 100,0 ± 22,9 45,9 ± 13,9 118,3 ± 31,7 55,2 ± 11,6
Turnover ratio SEM % SEM % SEM % SEM % SEM
Acad 0,765 ± 0,07 100,0 ± 9,34 74,7 ± 10,6 171,6 ± 20,4 109,4 ± 24,2
Nac 1,163 ± 0,11 100,0 ± 9,24 52,6 ± 6,8 168,1 ± 17,6 66,3 ± 14,7
CP 1,639 ± 0,18 100,0 ± 10,91 67,4 ± 8,2 131,9 ± 8,4 71,5 ± 14,7
Amy 0,321 ± 0,03 100,0 ± 9,91 98,5 ± 19,6 213,6 ± 16,5 67,6 ± 12,8
dHC 1,121 ± 0,12 100,0 ± 11,12 74,2 ± 8,4 145,8 ± 12,7 121,7 ± 29,7
PVN 0,330 ± 0,02 100,0 ± 7,55 70,6 ± 14,8 190,1 ± 6,8 85,7 ± 14,2
vHC 0,499 ± 0,07 100,0 ± 14,76 102,1 ± 24,0 164,9 ± 11,0 86,2 ± 12,4
DR 0,550 ± 0,05 100,0 ± 9,09 83,2 ± 9,9 182,5 ± 13,2 121,2 ± 21,7
MRN 0,949 ± 0,14 100,0 ± 15,02 63,2 ± 1,8 141,4 ± 37,7 139,4 ± 19,6
5-HTP fmol SEM % SEM % SEM % SEM % SEM
Acad 102,8 ± 9,96 100,0 ± 9,69 66,9 ± 12,9 119,4 ± 17,7 60,1 ± 7,1
Nac 97,9 ± 43,48 100,0 ± 44,41 82,7 ± 18,2 187,6 ± 41,6 68,1 ± 20,6
CP 176,4 ± 29,35 100,0 ± 16,64 110,1 ± 24,5 112,4 ± 17,3 71,1 ± 17,1
Amy 83,8 ± 10,90 100,0 ± 13,01 64,2 ± 16,0 128,0 ± 19,6 65,7 ± 11,4
dHC 195,7 ± 44,74 100,0 ± 22,86 62,6 ± 10,8 125,2 ± 16,7 63,1 ± 14,8
PVN 218,9 ± 43,22 100,0 ± 19,75 93,5 ± 6,0 150,9 ± 26,6 84,1 ± 17,0
vHC 111,7 ± 14,82 100,0 ± 13,27 85,7 ± 12,7 115,2 ± 8,4 75,2 ± 13,3
DR 2178,4 ± 301,20 100,0 ± 13,83 83,8 ± 10,2 53,1 ± 2,7 115,6 ± 22,1
MRN 1328,9 ± 185,41 100,0 ± 13,95 70,2 ± 8,1 74,2 ± 9,4 80,8 ± 6,0
 
 
Table 1. Effect of acute and chronic treatment with citalopram in absence and presence of a 
washout period. Values of the control group (saline treated, saline challenge) are presented both 
in amount and % of basal level, values of all other groups are presented as % of control group 
(basal level). 
 




The present study confirms the general observation that synthesis, release and metabolism of 
serotonin are all diminished in response to acute antidepressant treatment, but steadily revert to 
normal levels following chronic treatment. This reduced functionality of inhibitory feedback 
mechanisms is commonly explained by a gradual desensitization of the serotonergic 
autoreceptors. However, in contrast with these observations, our data indicate that intracellular 
serotonin remains decreased even upon chronic treatment, both after washout or in presence of 
citalopram. The amount of serotonin stored intracellular depends on both synthesis and reuptake 
of previously released serotonin. Theoretically, if synthesis cannot keep up with the conditions of 
chronic reuptake inhibition as induced during prolonged treatment with SSRIs, depletion of these 
stores could occur. Previous studies report restored (Esteban et al., 1999;Stenfors and Ross, 
2002) or even increased levels of 5-HTP following chronic treatment (Moret and Briley, 1992), 
suggesting adaptation. However, in all cases a washout period was included which might have 
interfered. Like treatment itself, a certain period of drug absence after treatment could also 
induce pharmacological changes on the cellular level. During a washout period, resensitization or 
adaptation can take place, altering or even reversing the effects of chronic treatment (Neumaier et 
al., 1996). This is indeed confirmed by our own results, as both turnover and 5-HTP are 
increased after washout but showed opposite effects if no washout was included. In addition, 
storage was only further decreased upon treatment, which can be better explained by a 
simultaneous reduction in synthesis too. So arguably, the situation without washout, in presence 
of citalopram, more accurately depicts the neurochemical effects of the chronic treatment itself. 
Clinically, this is interesting too, as the pharmacological situation in presence of citalopram more 
closely resembles the clinical situation.  
Introducing a washout out period could bear some similarity with the clinical effect known as 
rebound depression. When suddenly discontinuing antidepressant therapy, patients have been 
reported to relapse into a depressive state, suffering from an immediate reversal of all therapeutic 
effects. In the present study, this is resembled by the situation after a washout, which shows the 
effects of a sudden discontinuation of treatment rather than the effect of the treatment itself. This 
is most obviously seen in the amygdala, thalamus and forebrain regions. Interestingly, these areas 
are reported to have a high density of 5-HT1B receptors, which control serotonin release and 
synthesis. In contrast to 5-HT1A receptors, these receptors do not desensitize, so under contitions 
of increased extracellular serotonin, both synthesis and release are continuously inhibited as a 
result of 5-HT1B receptor activation. A fall in extracellular levels due to sudden treatment 
discontinuation will reverse this process. The enhanced levels of 5-HIAA/5-HT ratio and 5-HTP 
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accumulation seen after washout indeed point at an increase in release and synthesis, 
respectively. This process might very well explain the clinical effect known as rebound. 
Consequently, the present study provides the neurochemical evidence to gradually phase out 
antidepressant treatment in order to prevent rebound effects.  
But almost as important as this finding, our observations also indicate that intracellular serotonin 
stores in the brain are slowly depleted during chronic treatment. Although it sounds rather 
alarming, the clinical interpretation of these results remains unclear. If the therapeutic effect of 
antidepressants should be assigned to increased levels of extracellular 5-HT, it seems to be a 
paradox that the total amount of brain serotonin gets depleted, which is a rather unwanted side-
effect in this case. On the other hand, it might be that the neurochemical basis of the therapeutic 
effect is not restricted to the extracellular level. By adjusting both metabolism and synthesis, the 
resetting of the serotonergic system as a whole could also attribute to therapeutic success.  
From the present study it can be concluded that, although a washout period after chronic 
treatment is generally thought to be essential in order to prevent pharmacological interference, it 
is the washout period itself that interferes with the effect of the chronic treatment. The reversal of 
effects observed after a washout might refer to the rebound effect seen in the clinic and supports 
a gradual discontinuation to prevent a relapse. 
It should also be noted that as a result of continuous reuptake inhibition and a decreased 
synthesis rate, intracellular serotonin stores are steadily depleted upon treatment. Further 
research should reveal how this affects the therapeutic effect of SSRIs as it is still unknown how 
to interprete this on a clinical level. 
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